Screenshot 2024-06-06 at 9.25.11 AM

How TG Therapeutics Gained Site Payment Efficiency and Accrual Accuracy with Auxilius

business documents on office table with smart phone and laptop computer and graph financial with social network diagram and three colleagues discussing data in the background

"With Auxilius, we could gain control around clinical finances and get accurate and timely payments out the door."

Daniel Gay-Betton
Associate Director of Clinical Vendor and Program Management, TG Therapeutics

The Challenge

"Nearly impossible to accurately substantiate and accrue payments"

As Associate Director of Clinical Vendor and Program Management, Daniel Gay-Betton oversees 60 site investigators across one phase 3 and one phase 4 clinical trial. As these complex trials progressed, multiple issues emerged that made efficient and effective financial management nearly impossible. 

First, clinical studies were not being closed out efficiently, and invoices were coming in late from sites’ understaffed finance teams, leading to data lags and delays.

Secondly, data reporting from vendors was both insufficient and untimely, further complicating the situation. 

Together, these issues made it extremely difficult to accurately substantiate and accrue payments for investigators and sites. And as a result, TG Therapeutics carried a significant accrual on their books – from 6 months to up to several years. 

It was clear to Daniel and the team that they needed a better way to manage their relationships with clinical sites and reconcile their balance sheet. 

About TG Therapeutics

TG Therapeutics, Inc. was founded with one goal in mind: To leverage scientific advances in B-cell biology to develop novel, non-chemotherapy medicines for patients with B-cell diseases, specifically autoimmune diseases. They currently have two phase 1 trials underway.

 

Company Profile

Company Stage: Public (404a)
Trials: 1 (Phase 3)

Therapeutic Focus: Autoimmune disorders
Tech Stack: Netsuite, Bioclinica

Auditor: Ernst & Young, LLP

 

The Solution

Proactive invoicing powered by Auxilius Investigator Intelligence

The need for a streamlined, accurate, and timely payment processes was urgent to comply with financial obligations and mitigate risk exposure. With Auxilius, TG Therapeutics realized that they could proactively generate invoices using the Auxilius investigator suite. They were also determined to maintain positive relations with their site partners through timely, accurate payments. 

To accomplish this, TG Therapeutics collaborated with Auxilius on a multifaceted solution:

1. Process and Procurement Refinement

TG Therapeutics overhauled its procurement and contracting process in collaboration with Auxilius. This resulted in a restructuring of their procurement process, providing full visibility into R&D spend. These new processes, enabled by Auxilius, mitigated large outstanding balances, reduced cash flow problems for sites, and enhanced SOC compliance.

2. Auxilius Investigator Intelligence Suite

The Auxilius Investigator Intelligence suite provided TG Therapeutics with enhanced analytics and reporting on site activity well above and beyond the current state. Not only did the added visibility improve decision-making, but TG could even start issuing auto-generated invoices based on transaction data pulled from Electronic Data Capture (EDC) systems.

This automation ensured transparent, timely, accurate payments, and replaced the manual, error-prone processes that had frustrated sites and CROs alike. 

Start Your Success Story

 

Results

From 12-month outstanding balances, to zero.
TG Therapeutics’ partnership with Auxilius yielded transformative improvements in payments accuracy and efficiency:
  • Achieved 100% on-time payment rate on the first day of the month across two major autoimmune studies.
  • Transitioned from extensive outstanding balances varying from 6-12 months to zero outstanding balances. 
  • Invoices automatically generated within one day of EDC data upload. 
  • Time savings in an accelerated financial close.